摘要
霍奇金淋巴瘤治疗的发展已成为肿瘤治疗发展的典范。早期仅考虑消除病灶的观念已被综合治疗和平衡各种治疗所代替。霍奇金淋巴瘤治疗的最终目标是在分析危险因素的基础上,根据初始治疗反应,进行个体化治疗,以提高临床治愈率。明确是否能通过正电子发射断层扫描(PET)检查获知患者对治疗的反应,以指导个体化治疗,可避免放疗引起的后期毒性反应。
The evolution of treatment for Hodgkin lymphoma over many years is a paradigm for the treatment of cancer in general. An early focus on disease elimination has been replaced by concerns about the amount and balance of different therapies. Eventually, the aim is to individualize management based on risk factors at presentation and response to initial treatment. Our current focus is on the role of PET imaging and whether a response：adapted approach guided by PET can individualize therapy such that radiotherapy and its attendant late toxicity that impacts on future quality of life and survival can be avoided altogether in a subset of patients.
出处
《世界临床药物》
CAS
2009年第5期276-279,共4页
World Clinical Drug
